CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-lik…
DOI 10.1055/s-0035-1549752
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Cummings, R Gentilella, C Nicolay, O Adetunji
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: We investigated the effect of baseline BMI on treatment with dulaglutide and active comparators in patients with T2DM with baseline HbA1c ≥7.5% (AWARD 1 – 5). The National Institute for Health and Care Excellence (NICE) recommends HbA1c ≥7.5% for initiation of GLP-1RA therapy. Methods: Post-hoc, by-study analyses of change in HbA1c and bodyweight in patients receiving once-weekly dulaglutide 1.5 mg (n…
Zitieren
Zitierempfehlung
M Cummings, R Gentilella, C Nicolay, O Adetunji (2015) Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and act…. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549752
Mit CareLit weiterarbeiten